Proanthocyanidins: Impact on Gut Microbiota and Intestinal Action Mechanisms in the Prevention and Treatment of Metabolic Syndrome

Redondo-Castillejo, Rocío; Garcimartín Álvarez, Alba; Hernández Martín, Marina; López-Oliva Muñoz, María Elvira; Bocanegra De Juana, Aranzazu; Macho González, Adrián; Bastida Codina, Sara; Benedí González, Juana María; Sánchez Muniz, Francisco José

Proanthocyanidins: Impact on Gut Microbiota and Intestinal Action Mechanisms in the Prevention and Treatment of Metabolic Syndrome

Download

ijms-24-05369.pdf (2.87 MB)

Official URL

https://doi.org/10.3390/ijms24065369

Publication date

2023

Publisher

MDPI

Citations

Exportar

URI

https://hdl.handle.net/20.500.14352/93075

Citation

Rocío Redondo-Castillejo, Alba Garcimartín, Marina Hernández-Martín, María Elvira López-Oliva, Aránzazu Bocanegra, Adrián Macho-González, Sara Bastida, Juana Benedí, Francisco J. Sánchez-Muniz. Proanthocyanidins: Impact on Gut Microbiota and Intestinal Action Mechanisms in the Prevention and Treatment of Metabolic Syndrome. International Journal of Molecular Sciences 2023, 24 (6) , 5369

Abstract

The metabolic syndrome (MS) is a cluster of risk factors, such as central obesity, hyperglycemia, dyslipidemia, and arterial hypertension, which increase the probability of causing premature mortality. The consumption of high-fat diets (HFD), normally referred to high-saturated fat diets, is a major driver of the rising incidence of MS. In fact, the altered interplay between HFD, microbiome, and the intestinal barrier is being considered as a possible origin of MS. Consumption of proanthocyanidins (PAs) has a beneficial effect against the metabolic disturbances in MS. However, there are no conclusive results in the literature about the efficacy of PAs in improving MS. This review allows a comprehensive validation of the diverse effects of the PAs on the intestinal dysfunction in HFD-induced MS, differentiating between preventive and therapeutic actions. Special emphasis is placed on the impact of PAs on the gut microbiota, providing a system to facilitate comparison between the studies. PAs can modulate the microbiome toward a healthy profile and strength barrier integrity. Nevertheless, to date, published clinical trials to verify preclinical findings are scarce. Finally, the preventive consumption of PAs in MS-associated dysbiosis and intestinal dysfunction induced by HFD seems more successful than the treatment strategy.